Kyowa Kirin and Kura Oncology have started a Japanese Phase II registrational study of oral menin inhibitor ziftomenib in ...

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Kyowa Kirin and Kura Oncology have started a Japanese phase II trial of ziftomenib, an oral menin inhibitor, for adults with relapsed or refractory NPM1‑mutated acute myeloid leukemia. The open‑label ...

HOUSTON -- Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor. A pooled ...

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...

Kyowa Kirin and Kura Oncology have begun a Phase II trial in Japan of ziftomenib for relapsed or refractory NPM1‑mutated AML, aiming for regulatory approval. In Iowa, legislators are debating whether ...

Credit: Kura Oncology and Kyowa Kirin. The approval was based on data from the single-arm, open-label phase 2 KOMET-001 trial, which evaluated ziftomenib, a menin inhibitor, in adults with R/R AML ...

SELLAS Life Sciences Group, Inc. has announced promising preclinical results for SLS009, a selective CDK9 inhibitor, in treating TP53 mutated Acute Myeloid Leukemia (AML) cells, which typically have ...

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel ...

Allo-HCT outcomes for TP53-mutated AML are similar across haploidentical, matched sibling, and matched unrelated donors. The study analyzed 451 patients, showing comparable 2-year overall survival and ...

What Is Revuforj, and Why Does It Matter? Revuforj (revumenib) is an oral medicine approved for treating a type of cancer called acute myeloid leukemia (AML) that affects your bone marrow and blood.